Issue link: http://sarahcannon.uberflip.com/i/1492123
0208/23SCB003/R6 In 2022, Sarah Cannon Research Institute (SCRI) formed a joint venture with US Oncology Research (USOR) to enhance clinical trial access and availability across the country. *Presentations highlighted in blue represent research that was conducted across SCRI and the Sarah Cannon Transplant & Cellular Therapy Network, a Network of nine FACT/ JACIE accredited transplant centers across HCA Healthcare. TANDEM TRANSPLANTATION AND CELLULAR THERAPY MEETINGS 2023 PRESENTATION CALENDAR 1 WEDNESDAY, FEBRUARY 15 TH 3:00pm - 4:30pm Eastern Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 3:00 - 4:30pm 4:15 - 4:30pm Royal Oral 18 A Phase 1 Study of ADI-001: Anti- CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies Neelapu SS, Stevens DA, Hamadani M, Frank MJ, Holmes H, Jacobovits A, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein B, Galimi F, Lai RK, Miklos DB Oral Abstract - Session B: Engineered Immune Cells - Session I THURSDAY, FEBRUARY 16 TH 12:45pm - 4:15pm Eastern Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 12:45 - 2:15pm 12:55 - 1:15pm Sabal Oral NA Far from Home: Improving Care for Traveling Patients and Caregivers Majhail NS ASTCT Spotlight Session: Cellular Therapy Tourism: The Good, the Bad, and the Ugly 1:00 - 2:30pm 1:05 - 1:25pm; 2:05-2:13 Grand 8A Oral NA Expanding Access to Cell Therapies: Community Based Delivery, and Academic POC Manufacturing Essell J Expanding Access to Cell Therapies: Community Based Delivery, and Academic POC Manufacturing 2:30 - 3:00pm 2:30 - 2:45pm Sago Oral 100 Utilizing Remote Patient Monitoring to Safely Manage Chimeric Antigen Receptor T-Cell Recipients in the Outpatient Setting Carelock T, Brooks KA, Haga B, Campo R, Flynn A, Cox T, Majhail NS NSG Oral Abstracts: Session 1 4:15 - 6:15pm 5:15 - 5:30pm Crystal J1/ J2+M Oral 116 Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy Martinez C, Logan B, Liu X, Dvorak CC, Madden L, Molinari L, Cowan MJ, Pai SY, Haddad E, Puck J, Kohn DB, Griffith LM, Pulsipher M, Leiding JW, Notarangelo LD, Torgerson T, Marsh RA, Cuvelier GD, Prockop S, Buckley RH, Kuo CY, Yip A, Hershfield MS, Parrott RE, Ebens CL, Moore TB, O'Reilly RJ, Kapadia M, Kapoor N, Satter LF, Burroughs LM, Petrovic A, Thakar MS, Chellapandian D, Heimall JR, Shyr DC, Bednarski JJ, Rayes A, Chandrakasaon S, Quigg TC, Davila BJ, DeSantes K, Eissa H, Goldman F, Rozmus J, Shah AJ, Lugt MV, Keller MD, Sullivan KE, Jyonouchi S, Seroogy C, Decaluwe H, Teira P, Knutsen AP, Kletzel M, Aquino V, Davis JH, Szabolcs P (PEDS) Best Abstracts
